Copenhagen, 20 March 2014 – Zealand Pharma A/S (“Zealand”) (NASDAQ OMX Copenhagen: ZEAL), announces financial results in line with guidance and important advances for the company’s portfolio of peptide based medicines, including the launch of Lyxumia®, for the twelve month period from 1 January to 31 December 2013.